Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Psychopharmacology|May 3, 2018
The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophreniaTanja Veselinović, Ingo Vernaleken, Hildegard Janouschek, et al.
Psychopharmacology|June 7, 2011
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteersTanja Veselinović, Holger Schorn, Ingo Vernaleken, et al.
Human Brain Mapping|November 30, 2006
'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigationIngo Vernaleken, Hans-Georg Buchholz, Yoshitaka Kumakura, et al.
Neuropsychiatric Disease and Treatment|May 8, 2018
Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretionTanja Veselinović, Ingo Vernaleken, Paul Cumming, et al.
Neuroimage|February 12, 2008
Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjectsIngo Vernaleken, Yoshitaka Kumakura, Hans-Georg Buchholz, et al.
The International Journal of Neuropsychopharmacology|February 3, 2005
High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophreniaIngo Vernaleken, Thomas Siessmeier, Hans-Georg Buchholz, et al.
Neurobiology of Aging|June 11, 2008
Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET studyYoshitaka Kumakura, Ingo Vernaleken, Hans-Georg Buchholz, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 27, 2007
Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography studyYoshitaka Kumakura, Paul Cumming, Ingo Vernaleken, et al.
The International Journal of Neuropsychopharmacology|August 22, 2012
Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availabilityIngo Vernaleken, Majken Klomp, Olaf Moeller, et al.
Neuroimage|November 28, 2009
Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's diseaseYoshitaka Kumakura, Erik H Danielsen, Albert Gjedde, et al.
Pageof 4